



Novartis India Limited
Registered Office:
Inspire BKC
7th Floor
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.com

June 28, 2024

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Sub: Outcome of the Meeting of the Board of Directors of Novartis India Limited (“the Company”) held on Friday, June 28, 2024.

With reference to the above-mentioned subject, we are pleased to inform that based on the recommendation of Nomination and Remuneration Committee and pursuant to the provisions of Section 161, 196, 203 and other applicable provisions of the Companies Act, 2013, and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, (**‘SEBI Circular’**), wherever applicable, we hereby inform that the Board of Directors of the Company at its meeting held today i.e. June 28, 2024 has approved the appointment of Mr. Falin Majmudar (DIN: 10681030) as Additional Director (designated as ‘Whole-Time Director’) of the Company:

Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Falin Majmudar (DIN: 10681030) as:-

- a) Additional Director of the Company with effect from June 28, 2024; and
- b) Whole-Time Director (designated as ‘Whole-Time Director’) of the Company for a period of 5 (five) years with effect from June 28, 2024 upto June 27, 2029 subject to the approval of the Members of the Company

The Company shall seek approval of the Members of the Company in due course and within the prescribed timelines, in accordance with the SEBI Listing Regulations, wherever required.

Mr. Falin Majmudar is not debarred from holding the office of Director by virtue of any SEBI order or any other such Authority.

The details as required under SEBI Circular along with his brief profile is given in **‘Annexure I’** to this letter.



Novartis India Limited
Registered Office:
Inspire BKC
7th Floor
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.com

This is for your information and records.

Thanking you.

Yours faithfully,

For Novartis India Limited

Maru
Chandni

Digitally signed by Maru Chandni
DN: dc=com, dc=novartis, ou=people,
ou=LE, serialNumber=3190945,
cn=Maru Chandni
Date: 2024.06.28 13:04:03 +05'30'

Chandni Maru
Company Secretary and Compliance officer.



Novartis India Limited
Registered Office:
Inspire BKC
7th Floor
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.com

Annexure 'I'

Mr. Falin Majmudar

S. No.	Particulars	Details
1.	Reason of Change	Appointment of Mr. Falin Ishwarlal Majmudar (DIN: 10681030) as Additional Director (designated as Whole-Time Director) of the Company.
2.	Date of appointment	June 28, 2024
	Term of appointment	As per the Company's Policy
3.	Brief Profile	<p>Falin Ishwarlal Majmudar has 31+ years of experience in Medical device and Pharmaceutical industry having expertise in Manufacturing, Supply Chain, External Supply Operations (ESO) and Project Management. Falin has done his Post graduation in Pharmacy from L M College of Pharmacy, Ahmedabad and Post Graduate Diploma in Business Management from Xaviers Institute of Management, Bhuvneshwar.</p> <p>He brings with him excellent Technical knowledge, Industry experience and Skills to handle challenging situations. He is resilient and has excellent interpersonal skills.</p> <p>Prior to Joining Novartis India Limited, he has worked in Johnson & Johnson Limited and GlaxoSmithKline Pharmaceutical Limited.</p>
4.	Disclosure of relationships between directors	None